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Endometrial and ovarian cancers predominately affect women after menopause, and
are more frequently observed in developed countries. These are considered to be
hormone-dependent cancers, as steroid hormones, and estrogens in particular, have
roles in their onset and progression. After the production of estrogens in the ovary
has ceased, estrogen synthesis occurs in peripheral tissues. This depends on the
cellular uptake of estrone-sulfate and dehydroepiandrosterone-sulfate, as the most
important steroid precursors in the plasma of postmenopausal women. The uptake
through transporter proteins, such as those of the organic anion-transporting polypeptide
(OATP) and organic anion-transporter (OAT) families, is followed by the synthesis and
action of estradiol E2. Here, we provide an overview of the current understanding of
this intracrine action of steroid hormones, which depends on the availability of the
steroid precursors and transmembrane transporters for precursor uptake, along with
the enzymes for the synthesis of E2. The data is also provided relating to the selected
transmembrane transporters from the OATP, OAT, SLC51, and ABC-transporter families,
and the enzymes involved in the E2-generating pathways in cancers of the endometrium
and ovary. Finally, we discuss these transporters and enzymes as potential drug targets.
Keywords: sulfatase, aromatase, 17beta-hydroxysteroid dehydrogenase, transporters, OATP, ABC-transporter
HORMONE-DEPENDENT CANCERS
Steroid hormones have important roles in human physiology, and the disruption of androgen,
estrogen, and progesterone actions are implicated in the development of hormone-dependent
cancers and benign hormone-dependent diseases. Hormone-dependent cancers include prostate,
breast, endometrial, and ovarian cancers, which comprise more than 20% of all cancers in humans,
and more than 35% of cancers in women (Ferlay et al., 2013). Indeed, in women, breast cancer is
the most frequent cancer in the developed world. In 2012, 1,671,149 new cases of breast cancer
were estimated worldwide, with 521,907 associated deaths. In the developed world, endometrial
cancer is the most common among gynecological cancers. Worldwide, there were 319,605 new
cases and 76,160 deaths from endometrial cancer in 2012 alone (Ferlay et al., 2013). The most
deadly of the hormone-dependent cancers is ovarian cancer. Worldwide, there were 238,719 new
cases and 151,905 deaths from ovarian cancer in 2012 (Ferlay et al., 2013).
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Cancers of the endometrium and ovary predominately affect
women after menopause, and they are more frequently observed
in developed countries. These enormous numbers of patients
and deaths attributed to these hormone-dependent diseases
demonstrate the uttermost importance of detailed understanding
of their pathophysiology, including the roles of the steroid
hormones.
Endometrial Cancer and Steroid Hormones
Endometrial cancer is the fourth most prevalent among all
cancers, and the eighth most deadly cancer in North American
and European women (Ferlay et al., 2013). The incidence of
endometrial cancer is also increasing, with more patients from
the premenopausal and peri-menopausal population (Sanderson
et al., 2017). Based on its histopathology, clinical manifestation,
and epidemiology, endometrial cancer cases can be classified
into two groups. Estrogen-dependent type I endometrial cancer
with endometrioid or mucinous histology includes 70–80%
of all cases. Type II endometrial cancer is characterized by
serous papillary or clear-cell histology, originates from atrophic
endometrium, and develops from intraepithelial carcinoma
(Amant et al., 2005; Ryan et al., 2005). Type II endometrial cancer
includes 20% of all cases, and it is usually considered as estrogen
independent.
Endometrial cancers also differ in their genetic alterations.
Type I tumors are commonly associated with microsatellite
instability and mutations in the PTEN, PIK3CA, K-RAS,
CTNNB1, and FGFR genes (Yeramian et al., 2013). Type II
endometrial cancers are associated with inactivation of the TP53
and TP16 genes, and with amplification of the ERBB, CCND1,
and CCNE1 genes (Yeramian et al., 2013; Murali et al., 2014).
Based on the recent integrated genomic characterization of
endometrial cancer, its classification into four categories has been
suggested: (i) cancers with mutations in DNA polymerase ε; (ii)
hypermutated cancers with microsatellite instability; (iii) cancers
with low frequency of DNA amplifications; and (iv) cancers with
high frequency of DNA amplifications (Kandoth et al., 2013). The
first three groups comprise endometrioid endometrial cancers,
and the last group includes serous and endometriod types of
endometrial cancers (Kandoth et al., 2013). The endometrioid
types have usually been considered as type I endometrial cancers,
while the poorly differentiated endometrioid endometrial cancer
(grade 3) was recently classified as type II endometrial cancer
(Murali et al., 2014).
Epidemiological studies have identified several risk factors for
the development of endometrial cancer, which include obesity
(Jenabi and Poorolajal, 2015), estrogen-only therapy, early
menarche, late menopause, and nulliparity, among others. Recent
studies have shown that both type I and type II endometrial
cancers share several risk factors (Setiawan et al., 2013), and
patients with these cancers show no difference in E2 and
progesterone blood levels, which suggest similar pathogenesis
(Wan et al., 2016). Obesity is an important risk factor for the
development of endometrial cancer. It is associated with higher
levels of circulating estrogens in postmenopausal women, as
adipose tissue can serve as a source of estrogens that are formed
from inactive precursors of adrenal or ovarian origin (Blouin
et al., 2009). Additionally, the high-risk population includes
patients treated with tamoxifen. This is the standard therapy for
the majority of the 1.6 million breast cancer patients identified
yearly worldwide (Ferlay et al., 2013), and also for patients with
Lynch syndrome, with over one million cases in Europe alone
(Hampel and de la Chapelle, 2011).
Most of the risk factors for the development of endometrial
cancer can be explained by the unopposed estrogen hypothesis.
According to this hypothesis, the exposure to endogenous or
exogenous estrogens in the absence of progesterone or synthetic
progestins increases the proliferation of endometrial cells and
the concurrent DNA replication errors. This can result in
somatic mutations and malignant transformations (Henderson
and Feigelson, 2000; Akhmedkhanov et al., 2001). In endometrial
cancer, estrogens drive proliferation via estrogen receptor α
(ERα), which belongs to the superfamily of nuclear receptors
and is encoded by ESR1. The presence of ERα is related to
early-stage cancer, while a shift in the ratio between ERα
and estrogen receptor β (ERβ) or loss of ERα are associated
with shorter disease-free survival (Saegusa and Okayasu, 2000;
Sakaguchi et al., 2002; Hu et al., 2005; Mylonas, 2010; Zannoni
et al., 2013). Progesterone opposes the action of estrogens and
stimulates differentiation, as supported by association of the
genetic variations in genes that encode the PRA and PRB
progesterone receptors with increased risk of endometrial cancer
(Lee et al., 2010).
Epidemiological evidence suggests that also elevated blood
levels of androgens, including testosterone, androstenedione,
and dehydroepiandrosterone-sulfate (DHEA-S), are associated
with greater risk of endometrial cancer (Lukanova et al.,
2004). Significantly increased serum concentrations of DHEA,
androstenedione, and testosterone were seen in patients with
type I endometrial cancer when compared to healthy women
(Audet-Walsh et al., 2011). Interestingly, an epidemiological
study in premenopausal women revealed no associations between
androgens and endometrial cancer (Clendenen et al., 2016).
The importance of androgens as etiological factors has been
supported also by the expression of the androgen receptor and
the presence of androgen-metabolizing enzymes in well and
moderately differentiated endometrial cancer (Gibson et al.,
2014). However, in contrast to epidemiological studies, these
in-vitro reports have suggested protective effects of androgens.
Currently, the role of androgens in endometrial cancer is thus not
well-defined, although higher blood concentrations of androgens
seen in patients with type I endometrial cancer, together with the
presence of the androgen receptor and androgen-metabolizing
enzymes in tissue samples, have suggested that androgens do
not serve only as precursors of estrogens, but probably have
discrete roles in the pathophysiology of this gynecological
cancer.
Ovarian Cancer and Steroid Hormones
Ovarian cancer is a heterogeneous disease that encompasses
five major types of tumors that show different etiologies, risk
factors, origins, molecular features, and clinical behaviors. These
tumors are mainly derived from non-ovarian tissues that have
colonized the ovaries. As much as 90% of all ovarian cancers
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are epithelial ovarian cancers. With a frequency of 70%, the
most common ovarian cancer is high-grade serous carcinoma
(which originates from serous tubal intraepithelial carcinomas
in the Fallopian tubes). This is followed by endometrioid
carcinoma and clear-cell carcinoma (both of which originate
from endometrial cells), at 10% frequency each, and then low-
grade serous carcinoma (which originates from benign lesion
in the ovary) and mucinous carcinoma (which originates from
gastrointestinal tissue), at 5% of all epithelial cancers (Binder
et al., 2015; Prat, 2015; Ramalingam, 2016). High-grade serous
ovarian carcinoma carries TP53 mutations, while low-grade
serous ovarian carcinoma has wild-type TP53, but mutations in
K-RAS, B-RAF, and other oncogenes (Rojas et al., 2016). Most
patients with ovarian cancer are diagnosed with advanced stage
disease and consequently have poor prognosis. Only 46% of these
patients survive for 5 years, and compared to other cancers, the
overall survival has not increased significantly in the last 40 years
(Bast, 2011).
Data from epidemiological studies suggest that ovarian cancer
depend on estrogens, although the precise roles of estrogens
have not yet been defined (Chura et al., 2009a). Epidemiological
studies (Women’s Health Initiative and Million Women Study)
(Anderson et al., 2003; Beral et al., 2007, 2015) have indicated
that both estrogen only and combined estrogen–progestin
hormone replacement therapies increase the risk of serous and
endometrioid ovarian cancer, but not of other types. Also, genetic
susceptibility studies have supported estrogens in the etiology of
ovarian cancer, as a single nucleotide polymorphism (SNP) in
the ESR2 gene, which codes for ERβ, and which is considered
a tumor suppressor, is associated with significantly increased
risk of ovarian cancer (Lurie et al., 2011). Moreover, in clinical
samples of ovarian cancer, ERα is widely expressed, while the
levels of ERβ expression are progressively lost during ovarian
cancer progression toward metastatic tumors (Rutherford et al.,
2000). Estrogens have also been reported to stimulate ovarian
cancer proliferation and to increase metastatic potential (Bai
et al., 2000; Park et al., 2008).
The observed beneficial effects of pregnancy and
increased incidence of ovarian carcinoma among women
with progesterone deficiency (Diep et al., 2015) imply that
progesterone and progestins might prevent the development
of ovarian cancer (Modan et al., 1998; Ho, 2003; Modugno
et al., 2012; Jeon et al., 2016). Protective effects of progesterone
have also been supported by the reduced PRA levels in ovarian
carcinoma compared to benign ovarian tissue (Ho, 2003). On
the other hand, a SNP in the PGR gene that influences the
levels of the encoded PRA and PRB does not affect the risk
of ovarian cancer (Pearce et al., 2008; Modugno et al., 2012).
Some epidemiological studies have indicated that circulating
androgens might also have roles in ovarian cancer, while other
studies have not supported androgens as an etiological factor (for
review, see Modugno et al., 2012).
The epidemiological data on the involvement of steroid
hormones in the etiology of ovarian cancer are thus currently
inconclusive, and in some cases contradictory. As ovarian cancer
predominately affects women after menopause, it might be
explained by a greater importance of steroid biosynthesis from
adrenergic precursors and their actions in tumor tissue compared
to the circulating hormone levels (Modugno et al., 2012). This is
supported by the presence and activity of androgen and estrogen
biosynthetic enzymes in epithelial ovarian cancer (Chura et al.,
2009b).
INTRACRINE ACTIONS OF STEROID
HORMONES
In higher primates and humans, steroid hormones act in
endocrine, paracrine, autocrine, and intracrine manners. In these
species, steroid hormones are formed in the endocrine glands
and also in peripheral tissues, from inactive precursors of adrenal
origin or de-novo from cholesterol. The biosynthesis and actions
of steroid hormones in humans thus differ importantly from the
situation in animal models, where steroid hormones are formed
exclusively in the endocrine glands and act in the target tissues
(Luu-The and Labrie, 2010). In humans, steroid hormones thus
act in the same (i.e., intracrine, autocrine) or the neighboring
(i.e., paracrine) cell(s) where they are formed. Steroid hormones
that are formed in a particular cell can activate the corresponding
intracellular receptors of the nuclear receptor superfamily, which
act as transcription factors. The activated receptor dimer then
binds to the hormone-responsive elements of DNA, which is
followed by binding of co-activators/co-repressors and other
indispensable components of the transcription machinery. In
this manner, steroid hormones regulate the expression of the
target genes over a time period of hours or days (for review,
see Hewitt et al., 2016). As genes that encode steroid hormone
receptors have several transcripts and splice variants, this brings
additional complexity to their mechanisms of action (for review,
see Prossnitz and Barton, 2011; Thomas and Gustafsson, 2011;
Hattori et al., 2016).
Steroid hormones can also activate membrane-bound
receptors, in terms of the covalently modified, palmitoylated
classical receptors of the nuclear receptor superfamily
(Levin, 2011), or G-protein-coupled receptors (Prossnitz
et al., 2008), or newly identified membrane receptors
(Romero-Sánchez et al., 2008). In this manner, they
activate intracellular signaling pathways, and can thus have
rapid effects that occur in the time frame of minutes or
hours.
It has been known for more than 30 years that steroid
hormones can be formed from inactive steroid precursors
in target peripheral tissues. The terms intracrine action
and intracrinology were coined by Labrie to describe the
mechanism of action where steroids are formed in the same
cell in which they exert their action (Labrie, 1991). Active
androgens and estrogens can be formed from inactive or less
active precursor steroid hormones, mainly DHEA, DHEA-S,
androstenedione, and estrone-sulfate (E1-S). The local formation
of steroid hormones thus has major roles in both normal
tissues, such as breast, muscle, skin, and bone (Suzuki
et al., 2005), and also in hormone-dependent tumor tissues,
which comprise up to 20% of all cancers (Ferlay et al.,
2013).
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DHEA-S as a Precursor for Androgen and
Estrogen Formation
Humans and other primates are unique in that their adrenal
glands (zona reticularis) produce large quantities of the inactive
steroid precursors DHEA, DHEA-S, and androstenedione, which
can be metabolized in peripheral tissues into active androgens
and estrogens. These reactions depend on the presence of
androgen and estrogen forming and inactivating enzymes (Labrie
et al., 1998, 2015). In this manner peripheral target tissues can
control and adjust the formation and inactivation of steroid
hormones according to local requirements.
Labrie et al. (1998) estimated that 30–50% of androgens
in men in their 50 and 60 s are formed in peripheral tissues
from inactive precursors from the adrenal gland, mainly as
DHEA and DHEA-S. In women after menopause, intracrine
formation is even more important, with up to 100% of estrogens
formed from the adrenal precursors DHEA and DHEA-S,
and de-novo synthesis of the androgen androstenedione from
cholesterol in the ovaries (Labrie et al., 1998; Fogle et al.,
2007).
Serum concentrations of DHEA change through life, with
production of DHEA andDHEA-S increasing during adrenarche,
after the age of 6–8 years. These increased circulating levels
of DHEA and DHEA-S are then maintained for two decades,
before they start to decline after the third decade of life (Labrie
et al., 1997). The levels of DHEA thus regress with advanced
age, where the rate of this regression differs among races; e.g.,
lower decreases in circulating DHEA-S levels have been reported
in Japanese women compared to Caucasians (Crawford et al.,
2009). In spite of this decline, the plasma concentrations of
DHEA andDHEA-S in adult men andwomen are still 200–3,000-
fold higher than those of testosterone, 2,000–20,000-fold higher
than those of 5α-dihydrotestosterone (5αDHT), and 30,000–
800,0000-fold higher than those of estradiol (E2) (Labrie et al.,
1998; Audet-Walsh et al., 2011; Giton et al., 2011) (Table 1), with
large inter-individual variability seen. Interestingly, increased
concentrations of DHEA-S have been reported for menopausal
transition, which might be related to the rise of luteinizing
hormone (Yasui et al., 2012).
In postmenopausal women, the daily production of DHEA
is 6–8 mg, with about 50% of this originating from the adrenal
gland, 20% from the ovarian theca cells, and the remaining 30%
from the circulating DHEA-S, through the action of sulfatase
(Yasui et al., 2012). In these women, plasma concentrations of
DHEA and DHEA-S are relatively high; at approximately 6.6
nM and 1.6 µM, respectively (Table 1). In contrast, plasma
concentrations of E1 and E2 are much lower, at 60 and 12–15
pM, respectively. DHEA and DHEA-S can serve as sources for
the local formation of androgens and estrogens. In peripheral
tissues, E2 can be synthesized from adrenal DHEA and DHEA-
S, and also from adrenal or ovarian androstenedione (Figure 1).
Androstenedione formed from DHEA or DHEA-S can be
further activated to testosterone, by the action of 17-ketosteroid
reductase type 5, which is better known as aldo-keto reductase
1C3 (AKR1C3). Testosterone can also be further activated to the
most potent androgen 5α-DHT, by 5α-reductases type 1 and 2
(Figure 1). In patients with endometrial cancer, plasma DHEA,
and androstenedione concentrations are increased (Audet-Walsh
et al., 2011) and are related to increased risk of endometrial
cancer (Potischman et al., 1996; Lukanova et al., 2004). Also, a
strong association between DHEA-S and breast cancer risk has
been reported (Key et al., 2002), while no association with DHEA
or androstenedione was seen for ovarian cancer (Modugno et al.,
2012).
Estrone Sulfate as a Precursor for
Estrogen Formation
Estrone-sulfate (E1-S) represents the most abundant estrogen
in the peripheral blood and an important steroid precursor
for estrogen formation after activation by sulfatase (STS)
and 17-ketosteroid reductases (HSD17B1, HSD17B7, or
HSD17B12) (Figure 1), with relatively high concentrations
in postmenopausal women (0.5–0.6 nM). E1-S levels are
associated with high body mass index (Jasonni et al., 1984),
which implies that E1-S originates mainly from adipose tissue.
Indeed, high concentrations of E1-S have been reported for
visceral adipose tissue as compared to blood, where local
concentrations are up to 60-fold higher compared to serum
(Labrie, 2003).
About 3-fold higher E1-S plasma concentrations were
reported for postmenopausal patients with endometrial cancer
type I, compared to control healthy women, while no significant
difference was seen between endometrial cancer type II and
healthy women (Audet-Walsh et al., 2011). This suggests that in
type I endometrial cancer, E1-S might represent a source for local
E2 formation, or might reflect increased metabolism of estrogens
in cancer tissue. The levels of E1-S are significantly decreased in
patients with endometrial cancer with less-differentiated tumors
and in patients with myometrial invasion and lympho-vascular
space invasion. On the other hand, the circulating levels of E1-S
are 2-fold higher in recurrent cases compared to non-recurrent
cases (Audet-Walsh et al., 2011). Also, in ovarian cancer, E1-
S may serve as a precursor for biosynthesis of E2. Chura et al.
(2009a) reported that the great majority of epithelial ovarian
cancer samples show E1 sulfatase activity and 17-ketosteroid
reductase activity, which promote the activation of E1-S to the
most potent estrogen E2. Additionally, ovarian cancer cell lines
have capacity for metabolism of E1-S to E1 and E2 (Ren et al.,
2015).
DHEA-S and E1-S can serve as precursors for active
steroid hormones. Although the levels of DHEA-S and E1-
S decrease after menopause, serum concentrations of these
precursors in postmenopausal women are sufficient for the
local formation and actions of steroid hormones. To reach the
sites of intracrine or paracrine action, DHEA-S and E1-S have
to cross several biological membranes. First, they have to be
extruded from their site of synthesis, and when they reach
the peripheral tissue, they have to be taken up by individual
cells.
Transporters for DHEA-S and E1-S
The key determinants of the eﬄux and uptake of
DHEA-S and E1-S are the membrane proteins known as
ATP-binding-cassette (ABC)-transporters (Ween et al., 2015),
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organic anion-transporting polypeptides (OATPs) (Obaidat
et al., 2012; Roth et al., 2012), organic anion transporters (OAT)
(Burckhardt and Burckhardt, 2011), and transporters encoded by
the members of solute carrier family 51 (SLC51) (Ballatori et al.,
2013) (Table 2). In peripheral tissues, these uptake transporters
have crucial roles in providing the steroid precursors for local
androgen and estrogen formation.
Organic Anion-Transporting Polypeptides
The OATPs are encoded by genes of the solute carrier for
organic anions (SLCO) family, where this OATP/SLCO family
comprises 11 members in humans. OATPs have been detected
in various cells and tissues of the human body (Roth et al.,
2012). Some OATPs, like OATP1A2, OATP2B1, and OATP4A1,
are ubiquitous, while OATP1B1 and OATP1B3 are restricted
to hepatocytes (Hagenbuch and Stieger, 2013). However, under
pathological conditions, such as in cancers, the OATP expression
pattern is changed (Obaidat et al., 2012). OATPs are anion
exchangers that mediate the cellular uptake of large (>300 Da)
organic, mostly negatively charged, molecules in a Na+- and
ATP-independent manner (Roth et al., 2012). Their physiological
substrates are bilirubin, bile acids, prostaglandins, thyroid
hormones, and conjugated steroid hormones, such as DHEA-
S and E1-S. OATP1A2, OATP1B1, OATP1B3, and OATP2B1
mediate the uptake of DHEA-S, while OATP1A2, OATP1B1,
OATP1B3, OATP2B1, OATP4A1, and OATP4C1 catalyze the
uptake of E1-S (Table 2). At least four members of the family (i.e.,
OATP1A2, OATP1B1, OATP1B3, OATP2B1) transport various
clinically applied drugs, in addition to endobiotics. Therefore,
these proteins are also key determinants of drug absorption,
distribution, and excretion (Kovacsics et al., 2016).
Organic Anion Transporters
The OATs are anion exchangers that are encoded by members
of the SLC22 gene family. Most OATs are polyspecific, as they
can transport structurally diverse, relatively hydrophilic, low
molecular mass (<500 Da) compounds. Several members of
the SLC22 gene family, including OAT1 and OAT3, are well-
established determinants of renal clearance, intestinal absorption,
and hepatic elimination of drugs (Burckhardt and Burckhardt,
2011; Koepsell, 2013). On the other hand, OATs are also
important in neurotransmitter homeostasis in the brain, and at
least four members of this family (i.e., OAT2, OAT3, OAT4,
OAT7) transport E1-S, while OAT3, OAT4, and OAT7 transport
DHEA-S (Koepsell, 2013) (Table 2). OAT2 is expressed in the
liver and kidney (Koepsell, 2013), and in adipose tissue (Human
Protein Atlas). OAT3 is expressed in the kidney, and also in the
blood-brain barrier (Burckhardt and Burckhardt, 2011), while
OAT4 localizes to the kidney, and is also present in the placenta,
where it mediates the uptake of DHEA-S that is crucial for
placental estrogen synthesis (Ugele et al., 2003).
Transporters Encoded by Solute Carrier
(SLC) 51 Gene Family (OSTα, OSTβ)
The human SLC51 gene family has only two members, SLC51A
and SLC51B, which are also known as organic solute transporter
(OST)α and OSTβ (Ballatori et al., 2013). OSTα and OSTβ are
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FIGURE 1 | Formation of active steroid hormones from DHEA-S and E1-S. In peripheral tissues, dehydroepiandrosterone sulfate (DHEA-S), and estrone-sulfate (E1-S)
serve as precursors for formation of active steroid hormones. DHEA-S can be activated to estradiol (E2) via androstenedione by the actions of sulfatase (STS),
3β-hydroxysteroid dehydrogenases type 1 and 2 (HSD3B1, HSD3B2), aromatase (CYP19A1), and the reductive 17β-hydroxysteroid dehydrogenases (HSD17B1,
HSD17B7, 17HSD12) or aldo-keto reductase (AKR1C3). E2 can also be formed from estrone sulfate (E1-S) by the action of sulfatase (STS) and reductive HSD17B.
DHEA-S can be activated to active androgens. The most potent androgen 5α-dihydrotestosterone can be formed from DHEA-S by the actions of STS and HSD3B1,
or HSD3B2 and AKR1C3, and 5α-reductases types 1 and 2 (SRD5A1, SRD5A2).
TABLE 2 | Characteristics of the most relevant E1-S and DHEA-S transporters.
Family Protein Gene Km for E1-S (µM) Reference Km for DHEAS (µM) Reference
OATPs 1A2 SLCO1A2 16–59 Lee W. et al., 2005 7 Kullak-Ublick et al., 1998
1B1 SLCO1B1 0.3–45 Tamai et al., 2001; Roth et al.,
2012
22 Kullak-Ublick et al., 2001; Roth
et al., 2012
1B3 SLCO1B3 58 Gui et al., 2008 >30 Cui et al., 2001
2B1 SLCO2B1 21 Tamai et al., 2001; Pizzagalli et al.,
2003
9 Pizzagalli et al., 2003
4A1 SLCO4A1 n.d. Tamai et al., 2000 – –
4C1 SLCO4C1 26.6 Yamaguchi et al., 2010 – –
OATs OAT2 SLC22A7 n.d. Kobayashi et al., 2005 – –
OAT3 SLC22A8 2.2 and 21.2 Burckhardt and Burckhardt, 2011 13 Nozaki et al., 2007
OAT4 SLC22A11 1.01 and 21.7 Burckhardt and Burckhardt, 2011 0.63 and 29.2 Burckhardt and Burckhardt, 2011
OAT7 SLC22A9 8.7 Burckhardt and Burckhardt, 2011 2.2 Burckhardt and Burckhardt, 2011
ABC ABCC1/MRP1 0.9 Conrad et al., 2002 5 Zelcer et al., 2003
ABCC4/MRP4 – 2 Zelcer et al., 2003
ABCC11/MRP8 – Arlanov et al., 2016 21 Bortfeld et al., 2006
ABCG2/BCRP 6.8 Imai et al., 2003 – Lee Y. J. et al., 2005
SLC51 OSTα/β SLC51A/B n.d. Ballatori et al., 2005 n.d. Ballatori et al., 2005
n.d.: not measured
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obligate heterodimers that transport bile acids and conjugated
steroids; i.e., E1-S and DHEA-S. OSTα and OSTβ act down the
concentration gradient of their substrates, and therefore they
may be involved in both eﬄux and uptake processes (Ballatori
et al., 2013, 2008). In humans, the SLC51A and SLC51B mRNAs
have been reported for many tissues, including intestine, kidney,
liver, testes, ovary, uterus, prostate, adrenal, and mammary gland
(Seward et al., 2003).
ATP-Binding-Cassette Transporters
There are 48 distinct ABC-transporters in humans, which
have been grouped into seven subfamilies, from ABC-A to
ABC-G (Ween et al., 2015). The ABC-transporters mediate
the active transport of various compounds across extracellular
and intracellular membranes, with the energy derived from
hydrolysis of ATP. Many ABC-transporters work as eﬄux
pumps, to extrude their substrates from cells. ABC-transporters
recognize a large variety of endogenous substances, and
also chemically distinct molecules, including clinically applied
drugs (Sarkadi et al., 2006). Overexpression of polyspecific
ABC-transporters in tumors results in increased extrusion of
drugs and can lead to resistance against multiple anti-cancer
agents, termed as multi-drug resistance (MDR) (Schinkel and
Jonker, 2003). The three major ABC-transporters implicated
in MDR are ABCB1 (Pgp, P-glycoprotein) (Sharom, 2014),
ABCC1, which is better known as MDR-associated protein
1 (MRP1) (Cole, 2014), and ABCG2, which is also known
as breast cancer resistance protein (BCRP) or mitoxantrone
resistance protein (MXR) (Ishikawa and Nakagawa, 2009). The
multispecific MDR transporters are proven determinants of
drug absorption, distribution, and excretion (Szakacs et al.,
2008).
Members of ABC-transporter family C (i.e., ABCC1,
ABCC4, ABCC11, ABCG2) transport large, negatively charged
molecules. ABCC1 (MRP1) is ubiquitous in the body, and
its main physiological substrates are leukotriene C4, and
various glutathione-conjugated, glucuronidated, or sulfated
compounds, including E1-S (Bodo et al., 2003; Cole, 2014).
ABCC4 (MRP4) is found throughout the human body and
transports molecules that are involved in cellular signaling,
such as cyclic nucleotides, eicosanoids, and conjugated steroids
(Slot et al., 2011). ABCC11 (MRP8) is found in brain, breasts,
lungs, liver, kidney, placenta, prostate, testes, and apocrine
glands, as well as in cancerous tissues (Kruh et al., 2007). Its
substrates are lipophilic anions, as well as cyclic nucleotides and
anticancer drugs (Bortfeld et al., 2006; Matsumoto et al., 2014).
ABCC1, ABCC11, and ABCG2 transport E1-S, while ABCC1,
ABCC4, ABCC11, and ABCG2 mediate excretion of DHEA-S
(Table 2).
Concerted (and possibly co-regulated) actions of OATPs,
OATs, transporters encoded by the SLC51 gene family, ABC-
eﬄux pumps, and biotransformation enzymes are needed
for the handling of potentially toxic endogenous (e.g., bile
acids) and exogenous (e.g., drugs) compounds (Sarkadi et al.,
2006). Similarly, united actions of these transporters and the
intracellular enzymes are required for maintenance of normal
steroid hormone homeostasis.
DISTURBED TRANSPORT AND ESTROGEN
ACTIONS IN GYNECOLOGICAL CANCERS
Changes in Uptake and Excretion of
Steroid Conjugates
Altered expression of OATPs (usually as up-regulation) has been
documented in different types of cancers. As these transporters
serve as mediators of the uptake of nutrients for tumor growth
and survival, and as they also bring anticancer agents into cancer
cells, they may have significant impact on cancer therapies (Li
and Shu, 2014). High levels of the steroid transporting OATPs
(i.e., OATP1A2, OATP2B1, OATP1B3, OATP4A1, OATP4C1)
have been suggested for breast cancer cells, as compared to
normal tissue (Pizzagalli et al., 2003; Al Sarakbi et al., 2006;Meyer
zu Schwabedissen et al., 2008; Wlcek et al., 2008). OATP1B3
has also been observed in endometrial carcinoma, where high
levels significantly correlated with type I tumors and longer
disease-free survival (Ogane et al., 2013) (Table 3). High levels of
OATP1B3 and lower levels of OATP1B1 have also been reported
in ovarian cancer samples (Arakawa et al., 2012; Furihata et al.,
2015; Thakkar et al., 2015) and cancer cell lines (Cho et al.,
2009; Chay et al., 2010; Svoboda et al., 2011; Lancaster et al.,
2013) (Table 3). In addition to OATP1B3 and OATP1B1, also
OATP2B1, OATP3A1, and OATP4A1 have been detected at the
mRNA level in ovarian cancer samples (Tamai et al., 2000).
Among the transporters encoded by the SLC22 genes, OAT2
has been detected in colorectal cancer (Tashiro et al., 2014), while
to date there are no studies on the expression of the SLC22 genes
that encode the OAT2, OAT3, OAT4, and OAT7 proteins, nor on
the transporters from the OST/SLC51 family in endometrial and
ovarian cancers.
ABC-transporters are commonly up-regulated in
chemoresistant cancers, and increased expression and
activity of these drug eﬄux pumps results in reduced cellular
accumulation of drugs (Ween et al., 2015). In endometrial
cancer, chemoresistance is the major problem in advanced and
recurrent cases (Chaudhry and Asselin, 2009). However, the data
on expression of ABC-transporters in endometrial cancer are
very limited. Among the steroid-transporting ABC-transporters,
ABCG2 has been observed at the mRNA and protein levels
in CD133+ Ishikawa endometrial cancer cells, which have
characteristics of cancer stem cells (Nakamura et al., 2010,
2014), (Ween et al., 2015). Expression of ABCC4 was detected
in the HEC-1A endometrial cancer cell line, where the mRNA
levels were suppressed by down-regulation of transcription
factor KLF9. Decreased expression of KLF9 has previously been
observed in endometrial cancers of stages II to IV (Simmen et al.,
2008).
In ovarian cancer, chemoresistance is typically observed
after initial sensitivity to platin-based and taxol-based therapies.
The great majority of patients with advanced ovarian cancer
develop MDR due to the overexpression of the ABC-transporters
(Auner et al., 2010). In ovarian cancer, expression of ABCC1
has been observed at the mRNA and protein levels in serous,
mucinous, clear-cell, endometrioid, and undifferentiated ovarian
cancer tissues (for recent review, see Ween et al., 2015). Across
multiple studies, positive immunohistochemical staining for
Frontiers in Pharmacology | www.frontiersin.org 9 June 2017 | Volume 8 | Article 346
Rižner et al. Steroid Uptake and Intracrine Action
TABLE 3 | DHEA-S and E1-S transporters and estrogen biosynthetic enzymes in endometrial cancer.
Gene Level Cell line Tumor tissue
Regulation Reference Regulation Reference
OATP1B3 Protein Cancer/adjacent tissue ↑ Ogane et al., 2013
ABCC4 mRNA β HEC-1A after down-regulation of
KLF9
Simmen et al., 2008
ABCG2 mRNA CD+133 Ishikawa cells, Expressed Nakamura et al., 2014
Protein CD+133 Ishikawa cells, Expressed Nakamura et al., 2014
HSD3B1 mRNA HHUA, Expressed Sugawara et al., 2004 Cancer/adjacent tissue ≈ Sinreih et al., 2013
HIEEC, Ishikawa, HEC-1A
Expressed
↑ HEC-1A/HIEEC
Hevir-Kene and Rižner, 2015
HSD3B2 mRNA HOUA, Expressed Sugawara et al., 2004 Cancer/adjacent tissue ≈ Sinreih et al., 2013
HIEEC, Ishikawa, HEC-1A
Expressed ↑ HEC-1A/HIEEC
Hevir-Kene and Rižner, 2015
CYP19A1 mRNA HHUA, HOUA, No expression Sugawara et al., 2004 Cancer/adjacent tissue, Low
expression, ≈
Pathirage et al., 2006; Smuc and
Rizner, 2009; Lépine et al., 2010;
Cornel et al., 2012
HIEEC, Ishikawa, HEC-1A Low
expression ↑ HEC-1A/Ishikawa
Hevir-Kene and Rižner, 2015
Protein Cancer/pre-/post-menopausal
endometrium, No staining
Human Protein Atlas
Activity HEC-1, HEC-1B, RL-95, Ishikawa;
No activity
Fournier and Poirier, 2009
HIEEC, Ishikawa, HEC-1A, No
activity
Hevir-Kene and Rižner, 2015
HSD17B1 mRNA HIEEC, Ishikawa, HEC-1A
Expressed, ↑ HEC-1A/HIEEC
Hevir-Kene and Rižner, 2015 Cancer/adjacent tissue, Low
levels
Smuc et al., 2006; Lépine et al.,
2010; Cornel et al., 2012
Decreased Smuc and Rizner, 2009; Lépine
et al., 2010
Increased in G1, ERα Cornel et al., 2012
Protein Cancer/pre-/postmenopausal
endometrium: 9% Cancer,
weak/negative/negative
Human Protein Atlas
HSD17B7 mRNA HIEEC, Ishikawa, HEC-1A
Expressed, ↑ HEC-1A/HIEEC
Hevir-Kene and Rižner, 2015 Cancer/adjacent tissue
Decreased
Smuc and Rizner, 2009; Lépine
et al., 2010
Unchanged Lépine et al., 2010; Cornel et al.,
2012
Protein Cancer/pre-/postmenopausal
endometrium: 45% Cancer,
weak/weak/weak
Human Protein Atlas
HSD17B12 mRNA HIEEC, Ishikawa, HEC-1A
Expressed, ↑ HEC-1A/HIEEC
Hevir-Kene and Rižner, 2015 Cancer/adjacent tissue,
Unchanged
Smuc and Rizner, 2009
No significant difference Cornel et al., 2012
EC type 2; Increased Lépine et al., 2010
Protein Cancer/pre-/postmenopausal
endometrium: 45% Cancer,
weak/weak/weak
Human Protein Atlas
(Continued)
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TABLE 3 | Continued
Gene Level Cell line Tumor tissue
Regulation Reference Regulation Reference
HSD17B2 mRNA HIEEC, Ishikawa, HEC-1A
Expressed ≈
Hevir-Kene and Rižner, 2015 Cancer/adjacent tissue, EC type
2; Increased
Lépine et al., 2010
EC type 1; ≈ Increased in G2 Cornel et al., 2012
EC type 1 postmenopausal;
Increased
Lépine et al., 2010; Sinreih et al.,
2013
Protein Cancer/pre-/postmenopausal
endometrium; Moderate/
moderate/moderate
Human Protein Atlas
AKR1C3 mRNA HIEEC, Ishikawa, HEC-1A
Expressed, ↑ Ishikawa,
HEC-1A/HIEEC
Hevir-Kene and Rižner, 2015 Cancer/adjacent tissue;
Increased in individual patients
Rizner et al., 2006
No sign. difference Smuc and Rizner, 2009
Cancer/adjacent tissue;
Increased trend in G2/G3 EC
Cornel et al., 2012
Protein Cancer/pre-/post-menopausal
endometrium: 45% Cancer
moderate/strong/strong
Human Protein Atlas
STS mRNA HIEEC, Ishikawa, HEC-1A
Expressed
Hevir-Kene and Rižner, 2015 Cancer/adjacent tissue; ≈ Smuc and Rizner, 2009
Increased Lépine et al., 2010
Protein Cancer/pre-/postmenopausal
endometrium: 82% Cancer
weak-moderate/weak/weak
Human Protein Atlas
Activity
E1-S
HEC-1A, HEC-1B, RL-95,
Ishikawa; Low activity in whole
cells, higher activity in
homogenates
Fournier and Poirier, 2009
AC-258 Milewich and Porter, 1987
SULT1E1 mRNA Control HIEEC, Ishikawa, HEC-1A
Expressed ≈
Hevir-Kene and Rižner, 2015 Cancer/adjacent tissue type 1
and 2; Borderline increase
Lépine et al., 2010
Cancer/adjacent tissue type 1 ≈ Hevir et al., 2011
Protein Cancer/pre-/postmenopausal
endometrium: Not detected,
Negative/moderate/negative,
Not detected
Human Protein Atlas
SULT2B1 mRNA HIEEC, Ishikawa, HEC-1A
Expressed, ↑ Ishikawa and
HEC-1A/HIEEC
Hevir-Kene and Rižner 2015 Cancer/adjacent tissue;
Increased
Hevir et al., 2011
Protein Cancer/pre-/postmenopausal
endometrium: Moderate/
moderate/moderate
Human Protein Atlas
Endometrial cancer cell lines: HHUA, Ishikawa, well differentiated cell lines; RL-95, moderately differentiated cell line; HOUHA, HEC-1A, HEC-1B poorly differentiated cell line; HIEEC:
control cell line of normal endometrium (pre-menopausal).
ABCC1 (MRP1) has been seen in 22–68% of paraffin sections
from ovarian cancers (for review. see Ween et al., 2015), with
association with higher tumor grade reported (Bagnoli et al.,
2013). Also ABCC4 is expressed in ovarian cancers. In a study
that included 127 patients with ovarian cancer, ABCC4 (MRP4)
was associated with shorter progression-free survival (Bagnoli
et al., 2013; Ween et al., 2015). Finally, ABCC11 and ABCG2
have also been detected in ovarian cancers; the ABCG2 as a
marker of side-populations of ovarian cancer cells that show
stem-cell characteristics (Ween et al., 2015). In the ABCG2 gene,
several SNPs with functional consequences have been described,
although controversial data have been reported considering their
association with the outcome of ovarian cancers (for review, see
Ween et al., 2015). ABCG2 was induced in patients after their
chemotherapy, and also by estrogens in the PA-1 ovarian cancer
cell line after stable transfection with the gene encoding ERα (for
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FIGURE 2 | Uptake, intracrine action, and excretion of steroid hormones. The major players in intracrine estrogen action are depicted, with the additional data on the
levels of OATP, OAT, and ABC-transporters in endometrial (red arrows) and ovarian cancers (blue arrows).
review, seeWeen et al., 2015). Recent systematic genomic analysis
and biological properties of ovarian cancer cell lines showed that
many commonly used “ovarian cancer” cell lines are unlikely
to originate from high-grade serous ovarian cancer (Domcke
et al., 2013; Haley et al., 2016). Therefore, novel cancer cells lines
recently established will provide better models (Kreuzinger et al.,
2015).
Analysis of The Cancer Genome Atlas data for the SLCO
and SLC22 genes in endometrial and ovarian cancers (cbioportal;
http://www.cbioportal.org) (Cerami et al., 2012; Gao et al., 2013)
has provided further information. The SLCO1A2, SLCO1B1,
SLCO1B3, SLCO1C1, SLCO2B1, and SLCO4A1 genes were
amplified in <1% of patients, but showed mutations (as
mainly missense mutations), in 3.1–5.6% of 240 patients
with endometrial cancer. A similar trend was seen for the
SLC22 genes. Mutations were detected in all four SLC22A
genes (i.e., SLC22A7, SLC22A8, SLC22A11, SLC22A9), in 2.6–
5.1% of all patients. Among the ABC genes, there were
mutations in all four genes involved in the eﬄux of steroid
conjugates (i.e., ABCC1, ABCC4, ABCC11, ABCG2), in 5.7–
8.3% of patients with endometrial cancer. In contrast, the
SLCO1A2, SLCO1B1, SLCO1B3, SLCO1C1, SLCO2B1, and
SLCO4A1 genes were amplified in 4.7–7.4% of a total of
316 patients with serous ovarian cancer, with concurrent
amplification of SLCO1A2/1B1/1B3/1C1 and SLCO1B1/1B3/1C1,
and also SLCO1B3/1C1. Among the SLC22 and ABC genes,
SLC22A7 and ABCC1 were amplified in 3.5 and 2.5% of patients,
respectively, with serous ovarian cancers.
Although, the current knowledge on transporters in
endometrial cancer are scarce, the currently available data
suggest that E1-S and DHEA-S might enter cancerous cells via
OATP1B3, which is present mainly in type I tumors (Ogane
et al., 2013) (Table 3, Figure 2). This uptake might be affected
by the missense mutations seen in 5.1% of patients (cbioportal;
http://www.cbioportal.org). On the other hand, excretion of
steroid conjugates can be catalyzed by ABCC4, a high affinity
DHEA-S transporter that shows down-regulated expression in
advanced stages of cancer (III-IV) (Simmen et al., 2008) (Table 4,
Figure 2). Similarly, increased levels of ABCG2 were observed in
CD133+ Ishikawa cells (Nakamura et al., 2014). Again, further
regulation is achieved by mutations of ABCC4 and ABCG2, in
6.2 and 5.7% of patients, respectively (cbioportal; http://www.
cbioportal.org).
The published data reveal that in ovarian cancer, E1-S and
DHEA-S can enter cancer cells via higher levels of OATP1B3,
and also other OATPs might contribute, such as OATP1B1
(Table 2). Uptake of these steroids might be further regulated
by SLCO gene amplification (cbioportal; http://www.cbioportal.
org). This uptake is opposed by the excretion that is catalyzed
by ABCC1, ABCC4, and ABCG2, where ABCC1 and ABCG2
have the highest affinities for E1-S and DHEA-S, respectively.
Amplification of genes such as ABCC1 and ABCG2 further
modulate the excretion (cbioportal; http://www.cbioportal.org).
Altered Formation of Androgens and
Estrogens
In endometrial and ovarian cancers, several genes that encode
the enzymes for local androgen and estrogen formation from
precursor steroid conjugates are expressed, and some are
differentially regulated (Tables 3, 4).
Expression of the individual estrogen and androgen
biosynthetic genes in endometrial cancer has been studied
by several groups (for review, see Rižner, 2013). Expression of
STS, which is required for the hydrolysis of E1-S and DHEA-S,
was seen to be high and unchanged (Smuc and Rizner, 2009)
or increased (Lépine et al., 2010) in cancer tissues compared
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TABLE 4 | DHEA-S and E1-S transporters and estrogen biosynthetic enzymes in ovarian cancer.
Gene Level Cell line Tumor tissue
Regulation Reference Regulation Reference
OATP1B1 mRNA ↑ Serous epithelial
adenocarcinoma/control tissue
Svoboda et al., 2011
OATP1B3 mRNA IGROV1, OVCAR-3, OVCAR-4,
OVCAR5, OVCAR-8, SK-OV-3,
Expressed
Lancaster et al., 2013 Cancer/control tissue ↑ Lancaster et al., 2013
OVCAR-3, SK-OV-3, Expressed,
↑ OVCAR-3/SK-OV-3
Svoboda et al., 2011 ↑ Serous epithelial
adenocarcinoma/control tissue
Svoboda et al., 2011
OATP2B1 mRNA ↑ Serous epithelial
adenocarcinoma/control tissue
Svoboda et al., 2011
OATP4A1 mRNA ↑YDOV-151 (mucinous
adenocarcinoma), SK-OV-3/HOSE
Cho et al., 2009 ≈ Serous epithelial
adenocarcinoma/control tissue
Svoboda et al., 2011
↑YDOV-139 (serous carcinoma) Chay et al., 2010
OATP4C1 mRNA ≈ Serous epithelial
adenocarcinoma/control tissue
Svoboda et al., 2011
ABCC1 mRNA Expressed in serous, mucinous,
clear cell, endometrioid,
undifferentiated cancer
Reviewed by (Ween et al.,
2015)
Protein Positive IHC in 22–68% of ovarian
cancers
Reviewed by (Ween et al.,
2015)
ABCC4 Protein 127 OC patients; association with
shorter progress free survival
Bagnoli et al., 2013
ABCG2 Protein Induced in PA-1 OC cell line
transfected with ESR1
Ee et al., 2004 Expressed in OC, a marker of of OC
stem cells
Zhang et al., 2008
↑ resistant OC (carboplatin +
paclitaxel)
Ween et al., 2015
STS mRNA ≈ EOC (9–10)/OSE (17) Ren et al., 2015
Protein 70% clear cell (32/45); 33% serous
(6/18); and 50% mucinous
adenocarcinoma (4/8)
Okuda et al., 2001
Expressed EOC and OSE Ren et al., 2015
17% Cancer low/moderate, Normal
ovary low (stromal cells)
Human Protein Atlas
Activity E1-S ↑ SKOV-3, PEO-1 vs. OSE Ren et al., 2015 ↑ STS ↓ progression-free survival,
epithelial OC (48), serous OC (34)
Chura et al., 2009a,b
OC-117 Milewich and Porter,
1987
SULT1E1 mRNA ↓ EOC (9–10)/OSE (17) Ren et al., 2015
Protein Expressed EOC and OSE Ren et al., 2015 17% Cancer moderate/normal ND Human Protein Atlas
Expressed Ren et al., 2015
Activity E1 ↑ SKOV-3, PEO-1 vs. OSE Ren et al., 2015
HSD17B1 Activity
E1→E2
↑ SKOV-3, PEO-1 vs. OSE Ren et al., 2015
HSD17B2 mRNA ↓ EOC (9–10)/OSE (17) Ren et al., 2015
Protein Expressed Ren et al., 2015
Activity E2 Epithelial OC (48), serous OC (34) Chura et al., 2009b
(Continued)
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TABLE 4 | Continued
Gene Level Cell line Tumor tissue
Regulation Reference Regulation Reference
AKR1C3 mRNA ↓ EOC (9–10)/OSE (17) Ren et al., 2015
Protein Expressed Ren et al., 2015
Activity T Epithelial OC (48), serous OC (34) Chura et al., 2009b
HSD3B1/2 Activity DHEA Epithelial OC (48), serous OC (34) Chura et al., 2009b
EOC, epithelial ovarian carcinoma; OSE, ovarian surface epithelia; OCCA, ovarian clear-cell adenocarcinoma, IGROV1, OVCAR-3, OVCAR-4, OVCAR5, OVCAR-8, SK-OV-3, AC-258,
OC-117, PEO-1; ovarian cancer cell lines.
to control endometrial tissue. SULT1E1 opposes the action of
STS. However, the expression data for SULT1E1 mRNA are
controversial, with low and increased (Lépine et al., 2010) or
unchanged (Hevir et al., 2011) expression reported for cancer
tissue, as compared to control endometrium. In model cell lines
for well (Ishikawa cells), moderately (RL-95 cells), and poorly
(HEC-1A, HEC-1B cells) differentiated endometrial cancer (see
Supplementary Table 1) sulfatase activity was detected in whole
cells and in cell homogenates (Fournier and Poirier, 2009).
There was no difference in the expression of SULT1E1 between
the HIEEC control endometrial cell line and the HEC-1A
endometrial cancer cell line (Supplementary Table 1) (Hevir-
Kene and Rižner, 2015). Among the enzymes that catalyze the
activation of E1 to E2 (Figure 1), the mRNA levels of HSD17B1
were low (Smuc et al., 2006; Lépine et al., 2010; Cornel et al.,
2012), decreased (Smuc and Rizner, 2009; Lépine et al., 2010),
or increased in ERα-positive G1 cancers (Cornel et al., 2012).
The expression of HSD17B7 was unchanged (Lépine et al., 2010;
Cornel et al., 2012) or decreased (Smuc and Rizner, 2009), and
the expression of HSD17B12 was unchanged (Smuc and Rizner,
2009; Cornel et al., 2012) or increased (Lépine et al., 2010), in
endometrial cancer. In model cell lines, theHSD17B1,HSD17B7,
and HSD17B12 genes were up-regulated in HEC-1A vs. HIEEC
cells (Hevir-Kene and Rižner, 2015).
HSD17B2 catalyzes the oxidation of E2 back to the less potent
E1, and expression of the corresponding gene HSD17B2 was
increased in endometrial cancer (Lépine et al., 2010; Cornel
et al., 2012; Sinreih et al., 2013), while there was no difference
in expression of HSD17B2 among control and cancer cell lines
(Hevir-Kene and Rižner, 2015). The CYP19A1 gene encodes
aromatase and is responsible for the biosynthesis of E2 via
androstenedione or testosterone; this was weakly expressed in
cancer tissue, with no significant differences seen between cancer
and control endometrium (Pathirage et al., 2006; Smuc and
Rizner, 2009; Lépine et al., 2010; Cornel et al., 2012). In the
HHUA and HOUAmodel cell lines, CYP19A1 was not expressed
(Supplementary Table 1) (Sugawara et al., 2004), and there was
low expression in HIEEC, Ishikawa, and HEC-1A cells (Hevir-
Kene and Rižner, 2015). In tissue samples, several reports showed
immunohistochemical staining for CYP19A1 in paraffin sections
of endometrial cancer, where both stromal and epithelial cells
were stained, and several reports have shown a lack of specific
staining (for review, see Rižner, 2013). Together with our current
experimental data (Sinreih et al., in review to Frontiers in
Pharmacology Research Topic), it appears that in endometrial
cancer the sulfatase pathway has a more important role in E2
formation.
Among enzymes that catalyze local androgen formation
from DHEA-S, in addition to STS, genes encoding HSD3B1,
and HSD3B2 showed no differences in expression between
endometrial cancer and control tissue (Sinreih et al., 2013)
(Figure 1). Also in the HHUA, HOUA, Ishikawa, HEC-1A, and
HIEEC model cell lines (Supplementary Table 1), these two
genes HSD3B1 and HSD3B2 were expressed, with higher mRNA
levels in the HEC-1A cells as compared to the control HIEEC
cells (Sugawara et al., 2004; Hevir-Kene and Rižner, 2015).
Additionally, the gene that encodes AKR1C3, which catalyzes
the activation of androstenedione to testosterone, was expressed
in cancer tissue, but with no significant difference seen between
cancer and adjacent control tissue, although with particularly
increased levels in individual patients (Rizner et al., 2006).
There was also a trend for increased expression of AKR1C3 in
G2/G3 cancers compared to G1 cancers (Cornel et al., 2012),
but there were also decreased levels of AKR1C3 reported in
cancer compared to control endometrium (Zakharov et al.,
2010). Interestingly, AKR1C3 was up-regulated in Ishikawa and
HEC-1A cells vs. the control HIEEC cells (Hevir-Kene and
Rižner, 2015). These data thus supports the capacity of cancerous
endometrium for formation of androgens from DHEA and
DHEA-S.
In ovarian cancer, STS is expressed at the mRNA and protein
levels in primary cell cultures, tissue samples, and model cell
lines (see Supplementary Table 2) (Ren et al., 2015; Okuda
et al., 2001), with no significant differences seen between
ovarian carcinoma and ovarian surface epithelial cells. Using
immunohistochemistry, STS was detected in 70% of clear cells,
and in 33% of serous and 50% of mucinous tumors (Okuda
et al., 2001). High STS activity was detected in epithelial ovarian
cancer tissue (Chura et al., 2009a), and also in the SKOV-3 and
PEO-1 ovarian cancer cell lines (Supplementary Table 2). STS
activity was higher in the model cell lines than in control ovarian
surface epithelia cells (Ren et al., 2015). Significantly decreased
expression of SULT1E1 was seen at the mRNA level in epithelial
ovarian cancer cells compared to ovarian surface epithelial cells
(Ren et al., 2015).
In addition to STS activity, other enzymatic activities that are
also necessary for local formation of androgens and estrogen
have been observed in tissue samples of ovarian cancer, including
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conversion of DHEA to androstenedione, and conversions
between E2, E1, testosterone, and androstenedione (Chura et al.,
2009b). The enzymes that catalyze these reactions (i.e., HSD17B2,
AKR1C3, SULT1E1) were detected by immunohistochemistry in
ovarian cancer tissue samples (Ren et al., 2015). The importance
of the local formation of E2 via the sulfatase pathway is supported
by high levels of STS and significantly down-regulated SULT1E1
together with metabolism of E1-S to E1 (Milewich and Porter,
1987; Chura et al., 2009a) and E2 (Ren et al., 2015) in tissue
samples and model cell lines of ovarian cancer. In ovarian cancer
samples, androstenedione can be formed from DHEA (Chura
et al., 2009a), although Ren et al. (Ren et al., 2015) found no
evidence for further formation of estrogens via the aromatase
pathway or activation of androstenedione to testosterone and
5α-dihydrotestosterone, as also supported by down-regulation of
AKR1C3. However, in other studies, CYP19A1 was expressed in
stroma cells of ovarian cancers (Manna et al., 2016), and has been
considered a target for an endocrine therapy (Langdon et al.,
2017).
PHARMACOLOGICAL INTERVENTIONS
THAT TARGET INTRACRINE ACTIONS
Endometrial and ovarian cancers are considered to be hormone-
dependent cancers. As they develop mainly in postmenopausal
women, they depend on local formation of active estrogens,
while the roles of androgens are currently not fully understood.
After menopause, the intracrine production of estrogens from
the steroid precursors E1-S and DHEA-S in cancer cells can
theoretically be blocked in a number of ways, including: (i)
prevention of transporter-mediated uptake of E1-S and DHEA-
S from the circulation; (ii) inhibition of enzymes in the intracrine
pathway for the formation of active estrogens by the so-called
selective intracrine modulators; (iii) prevention of estrogen
actions via ERα; and (iv) induction of estrogen inactivation
and excretion from cancer cells via the ABC-eﬄux pumps,
which will decrease their intracellular concentrations. Strategies
for targeting transporters, receptors and enzymes in intracrine
pathways in endometrial and ovarian cancers are discussed in
more detail in the following sections, with comparisons also from
several studies in breast cancer.
Sulfatase and 17-Ketosteroid Reductase
Type 1 as Novel Drug Targets
Previous studies have suggested that in the endometrium
and ovary of postmenopausal women, hydrolysis of sulfated
precursors is the major pathway for the generation of active
estrogens. Indeed, STS inhibitors have been successfully tested
in preclinical and animal models of hormone-dependent
cancers (for an extensive review on E1 sulfatase inhibitors
and their efficacy in animal and human tumor models, see
Thomas and Potter, 2015; Rižner, 2016). Irosustat (STX64)
is a potent tricylic coumarin-based sulfamate that irreversibly
blocks STS activity, and it has been examined in phase II
clinical trials for the treatment of patients with advanced
hormone-dependent breast and endometrial cancers (Stanway
et al., 2007). Although the breast cancer data have not yet
been published (ClinicalTrials.gov Identifier: NCT01662726)
https://clinicaltrials.gov/ct2/show/NCT01662726), the effects in
endometrial cancer were not as good as the effects of
medroxyprogesterone acetate, which is in clinical use for cases
of advanced/ recurrent cancer (Pautier et al., 2012).
Estrone formed by the sulfatase pathway has to be activated
by reductive HSD17B enzymes, where HSD17B1 has the highest
catalytic efficiency (Rižner, 2013). The inhibitors of reductive
HSD17B1 enzymes can block the conversion of E1 to E2,
and have potential for application to hormone-sensitive cancer
therapy. Although the mRNA and protein levels of HSD17B1
are very low, this approach might be interesting for treatment
of endometrial cancer, as recent reports have shown correlations
between increased HSD17B1 mRNA levels and poor prognosis
(Cornel et al., 2017). This approach might also be useful in
ovarian cancer, as increased reduction of E1 to E2 has been seen
in ovarian cancer cells (Ren et al., 2015). Indeed, compounds have
been developed that show promising inhibition of E2 formation
from E1 in vitro (Brozic et al., 2008; Mazumdar et al., 2009),
although none of these have been studied in clinical trials to date.
Most likely they will not be highly effective as mono-therapeutic
agents, because they prevent the conversion of a weak estrogenic
E1 to the most potent estrogen E2 only, but they might be
useful in combination with other inhibitors, such as inhibitors
of STS.
Even if the production of E2 via the sulfatase pathway exceeds
that of the aromatase pathway, blocking one enzyme might up-
regulate the others. Such a mechanism was recently reported
for ERα-positive breast cancer cell lines, where resistance to
aromatase inhibitors was associated with up-regulation of STS
and E1-S transporting OATPs (Higuchi et al., 2016). Therefore,
as a consequence of inhibition of STS, the low expression levels
of CYP19A1 in endometrial and ovarian cancers (Manna et al.,
2016) might be up-regulated as well. In this case, a combination
of inhibitors for STS and CYP19A1 might be useful. After
the introduction in around 1980 of aminoglutethimide as the
first aromatase inhibitor with documented anti-cancer efficacy
(Samojlik et al., 1980), the third-generation aromatase inhibitors
letrozole and anastrozole, and exemestane, are currently used
for treatment of postmenopausal breast cancer (Smith and
Dowsett, 2003). However, in endometrial cancer, aromatase
inhibitors have shown only weak effects (Bogliolo et al., 2016).
For recurrent ovarian cancer their application has been suggested
as well and remarkably positive effects were reported for a
patient with endometrioid ovarian cancer (Pan and Kao, 2010).
Dual CYP19A1-STS inhibitors have also already been designed,
where the sulfatase inhibitory pharmacophore was integrated
into an established aromatase inhibitor (sulfamate derivatives
of letrozole and anastrozole), or vice versa (Woo et al., 2010;
Harrelson and Lee, 2016). In a similar manner, dual HSD17B1/
STS inhibitors also represent a plausible approach in future drug
discovery.
For further drug development, compounds from natural
sources with dual aromatase and sulfatase inhibitory activities
might also be of interest, such as a traditional Chinese
herbal formula (Shu-Gan-Liang-Xue decoction) that is used for
treatment of patients with breast cancer in traditional Chinese
medicine (Zhou et al., 2014).
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Estrogen Receptor α as a Drug Target
The activation of ERα by estrogens can be prevented by
antagonists or selective estrogen receptor modulators (SERMs).
There is an important difference between these compounds, as
antagonists block estrogen action in all tissues, while SERMs can
act as agonists in certain tissues, and as antagonists in other
tissues, where their actions depend on the availability of co-
activators and co-repressors (Traboulsi et al., 2017). The best
studied SERM is tamoxifen, which has been successfully applied
in the treatment of hormone-receptor-positive breast cancer
for more than 40 years (see Scharl and Salterberg, 2016). In
endometrium, tamoxifen has estrogenic effects and stimulates
cell proliferation, which leads to hyperplasia, and eventually, to
endometrial cancer (Ellis et al., 2015). Only recently has concern
arisen that tamoxifen might also increase the risk of ovarian
cancer, as it promotes lesions in the fallopian tubes and ovaries
(Chene et al., 2014). Novel SERMs have been developed to
combat estrogen-dependent cancers, including toremifene and
raloxifene, together with the selective ER down-regulators, such
as selective receptor downregulator fulvestrant (for reviews, see
Bogliolo et al., 2017; Traboulsi et al., 2017). Further clinical
studies on patients with endometrial and ovarian cancer are
currently awaited.
OAT, OATP, and ABC-Transporters as Novel
Drug Targets?
The E1-S– and DHEA-S–transporting OATPs are up-regulated
in endometrial and ovarian cancers. To prevent OATP-mediated
uptake of steroid hormone precursors into tumor cells, blocking
OATP transport would be required. Inhibition of OATP-
mediated uptake has been studied extensively using synthetic and
natural inhibitors of OATP1B3 andOATP1B1 to block the uptake
of statins and other substrates of these OATPs, both in vitro and
in animal studies. However, blocking the function of these two
liver-specific OATPs can change the hepatic clearance of drugs,
which can result in their altered pharmacokinetics (i.e., elevated
plasma levels of drugs are usually expected). This may cause
serious adverse reactions, such as statin-induced myotoxicity, as
has been demonstrated by co-administration of cyclosporine-
A and gemfibrozil with statins (for review, see Kalliokoski and
Niemi, 2009; Maeda, 2015).
Moreover, studies in breast cancer have revealed that
prevention of the expression of a single OATP is not sufficient to
inhibit steroid hormone uptake (Higuchi et al., 2016). Therefore,
simultaneous blocking of various OATPs would be required.
However, this would also influence the physiological functions
of OATPs, and would disturb the metabolic homeostasis and
protection against toxins. Therefore, the clinical application
of such a simultaneous block is questionable (Stieger and
Hagenbuch, 2014). Furthermore, in general, this block would
only work with the particular isoforms of the transporters that are
restricted to the cancerous tissues (Thakkar et al., 2015). To date,
only one cancer-specific isoform (cancer-type OATP1B3) has
been identified, although only in colon and pancreatic cancers
(Furihata et al., 2015). As the SLCO and SLC genes are amplified
in a subset of patients with ovarian cancer, their targeted
inhibitionmight be considered. Also mutations in SLCO and SLC
in endometrial cancer patients might allow the development of
mutation-specific inhibitors.
However, the evaluation of OATP and OAT transporters as
drug targets is currently precluded by the lack of complete
information about their biological functions, substrate
specificities, and mechanisms of action, and the importance
of the corresponding SLCO and SLC gene amplifications and
mutations in patients with endometrial and ovarian cancers.
Another option would theoretically be to limit the
concentrations of steroid precursors in tumor cells by increasing
steroid hormone eﬄux via ABC-transporters. Many ABC-
proteins are expressed at physiological barriers where they
protect cells and tissues against toxic compounds, which include
anticancer drugs (Chen et al., 2016). Some of these ABC proteins
are associated with drug resistance in ovarian and endometrial
cancers. For example, overexpression of ABCC1 and ABCG2
in serous ovarian cancer reduces the cellular accumulation of
anticancer drugs, and this leads to the development of MDR
and poor prognosis (Kunicka and Soucek, 2014; Elsnerova et al.,
2016). Furthermore, ABCC1 is associated with higher tumor
grade, and ABCC4 with reduced progression-free survival of
patients with ovarian cancer (Ween et al., 2015). Moreover,
in endometrial cancer, ABCG2 is expressed in the Ishikawa
model cell line, which is enriched in CD133 and has cancer
stem cell characteristics (Nakamura et al., 2010). Inhibitors of
ABC-transporters have thus been included in several clinical
studies that have targeted mainly ABCB1, and also ABCC1
and ABCG2 (for extensive review, see Ween et al., 2015).
However, these have not shown sufficient efficacy to block
ovarian cancer progression. Higher expression of these ABCs
should also lead to increased extrusion of steroid hormone
conjugates from the cancer cells. However, in terms of the
usually negative correlation between the expression levels of
these ABC-transporters and patient prognosis (see above), the
benefit of targeting these ABC-transporters with concurrent
decreased hormone levels will not counterweigh the MDR
induced.
Current Status and Future Prospects
In patients with advanced endometrial and ovarian cancers,
targeting ERα or enzymes for estrogen activation has not proven
to be successful to date (Secky et al., 2013; Mueller et al.,
2015). As a small subgroup of patients (∼20%) still responds
to estrogen-deprivation therapy, better stratification of patients
for menopausal status, hormone receptor status, and presence
of estrogen biosynthetic enzymes, among other factors, could
select a subpopulation that would most likely benefit from
estrogen-deprivation therapy. The development of resistance
to estrogen-deprivation therapy may be of major concern,
and therefore a combination of drugs instead of monotherapy
with one agent may extend the period of sensitivity to these
therapeutics. In this respect, dual STS/CYP191 inhibitors might
be important, as drugs also targeting ERα (ERα antagonists)
might be given together with STS and/or HSD17B1 inhibitors.
Very promising data have been reported for breast cancer, where
a combination of aromatase inhibitors and novel agents that
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target overexpressed kinases has led to enhanced therapeutic
responses (Zhao and Ramaswamy, 2014; Daldorff et al., 2017).
Elucidation of such novel approaches for endometrial and
ovarian cancer-specific pathways in combination with the
use of selective intracrine modulators or selective estrogen-
receptor modulators may lead to the development of novel
therapeutic approaches to improve the success of cancer
chemotherapy.
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